Chemotherapy Delivery Issues in Central Nervous System Malignancy: A Reality Check
Open Access
- 1 June 2007
- journal article
- review article
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 25 (16), 2295-2305
- https://doi.org/10.1200/jco.2006.09.9861
Abstract
Purpose: This review assesses the current state of knowledge regarding preclinical and clinical pharmacology for brain tumor chemotherapy and evaluates relevant brain tumor pharmacology studies before October 2006. Results: Chemotherapeutic regimens in brain tumor therapy have often emerged from empirical clinical studies with retrospective pharmacologic explanations, rather than prospective trials of rational chemotherapeutic approaches. Brain tumors are largely composed of CNS metastases of systemic cancers. Primary brain tumors, such as glioblastoma multiforme or primary CNS lymphomas, are less common. Few of these tumors have well-defined optimal treatment. Brain tumors are protected from systemic chemotherapy by the blood-brain barrier (BBB) and by intrinsic properties of the tumors. Pharmacologic studies of delivery of conventional chemotherapeutics and novel therapeutics showing actual tumor concentrations and biologic effect are lacking. Conclusion: In this article, we review drug delivery across the BBB, as well as blood-tumor and –cerebrospinal fluid (CSF) barriers, and mechanisms to increase drug delivery to CNS and CSF tumors. Because of the difficulty in treating CNS tumors, innovative treatments and alternative delivery techniques involving brain/cord capillaries, choroid plexus, and CSF are needed.Keywords
This publication has 94 references indexed in Scilit:
- Therapeutic implications of tumor interstitial fluid pressure in subcutaneous RG-2 tumorsNeuro-Oncology, 2006
- Targeted delivery of antibodies through the blood–brain barrier by MRI-guided focused ultrasoundBiochemical and Biophysical Research Communications, 2006
- Pharmacokinetics Following Intraventricular Administration of Chemotherapy in Patients with Neoplastic MeningitisClinical Pharmacokinetics, 2005
- Improved penetration of docetaxel into the brain by co-administration of inhibitors of P-glycoproteinEuropean Journal of Cancer, 2004
- Distribution of STI-571 to the Brain Is Limited by P-Glycoprotein-Mediated EffluxThe Journal of pharmacology and experimental therapeutics, 2002
- Cerebrospinal fluid concentrations of vincristine after bolus intravenous dosingCancer, 2002
- Pharmacokinetics and toxicity of high-dose intravenous methotrexate in the treatment of leptomeningeal carcinomatosisCancer Chemotherapy and Pharmacology, 2000
- Long-term Toxicity and Neuropathology Associated with the Sequencing of Cranial Irradiation and Enhanced Chemotherapy DeliveryNeurosurgery, 1997
- Cerebrospinal Fluid Drug Levels of Leukemic Children Receiving Intravenous 5 g/m2MethotrexateLeukemia & Lymphoma, 1994
- Cis-diamminedichloroplatinum (CDDP) therapy for brain metastasis of lung cancerJournal of Neuro-Oncology, 1993